Mongolia : Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility
The risk of continued community spread of the coronavirus disease (COVID-19) in Mongolia remains substantial. Since the first case of community transmission was reported on
10 November 2020, several clusters of local transmission have emerged in the capital city and six provinces.
Proposal. The Government of Mongolia officially requested ADB support for securing safe and effective COVID-19 vaccine. The proposed project seeks to provide a loan, through the Asia Pacific Vaccine Access Facility (APVAX) facility, amounting to $40 million to support COVID-19 vaccine delivery in Mongolia.
Project Details
-
Project Officer
Habib, Najibullah
Sectors Group
Request for information -
Country/Economy
Mongolia -
Sector
- Health
- Project Name
- Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility
- Project Number
- 55007-001
- Country / Economy
- Mongolia
- Project Status
- Active
- Project Type / Modality of Assistance
- Loan
- Source of Funding / Amount
-
Loan 4068-MON: Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility Source Amount Ordinary capital resources US$ 9.50 million Loan 4069-MON: Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility Source Amount Concessional ordinary capital resources lending US$ 9.50 million Loan 8399-MON: Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility Source Amount Asian Infrastructure Investment Bank US$ 21.00 million - Operational Priorities
- OP1: Addressing remaining poverty and reducing inequalities
- OP2: Accelerating progress in gender equality
- OP6: Strengthening governance and institutional capacity
- OP7: Fostering regional cooperation and integration
- Sector / Subsector
Health / Disease control of communicable disease
- Gender
- Some gender elements
- Description
The risk of continued community spread of the coronavirus disease (COVID-19) in Mongolia remains substantial. Since the first case of community transmission was reported on
10 November 2020, several clusters of local transmission have emerged in the capital city and six provinces.
Proposal. The Government of Mongolia officially requested ADB support for securing safe and effective COVID-19 vaccine. The proposed project seeks to provide a loan, through the Asia Pacific Vaccine Access Facility (APVAX) facility, amounting to $40 million to support COVID-19 vaccine delivery in Mongolia.
- Project Rationale and Linkage to Country/Regional Strategy
The request is aligned with ADB's access and eligibility requirements for APVAX. There is clear adverse socio-economic impact of the pandemic in Mongolia, and strong actions led by the government in implementing national COVID-19 response, and the vaccination strategy and plan. The government has also secured Mongolia's participation in COVAX AMC and coordinating its efforts with development partners, including WHO, UNICEF, the World Bank, and ADB. The government intends to purchase COVAX eligible WHO prequalified COVID-19 vaccines that meets ADB's vaccine eligibility criteria and requirements for financing under the Rapid Response Component of the APVAX.
- Impact
Morbidity and mortality of severe acute respiratory syndrome coronavirus 2 reduced
Project Outcome
- Description of Outcome
Priority population vaccinated against COVID-19 without disruption of primary health care services
- Progress Toward Outcome
- As of 3 June 2022, Mongolia received in total 8,397,550 doses of four different vaccines, mainly procured by the Government of Mongolia, as well as received as donations or procured by the private sector. These include Sinopharm (4,300,000), AstraZeneca (262,800), Pfizer BioNTech (3,714,750) and Sputnik V (120,000) vaccines against COVID-19.
Implementation Progress
- Description of Project Outputs
COVID-19 vaccines for priority population efficiently procured and delivered
Primary health care services for noncommunicable diseases disrupted by COVID-19 reestablished
Awareness on COVID-19 vaccination and delivery enhanced
- Status of Implementation Progress (Outputs, Activities, and Issues)
Eligible vaccines received by MOH.
To be closely monitored as data is not yet available.
- Geographical Location
- Nation-wide
Safeguard Categories
- Environment
- C
- Involuntary Resettlement
- C
- Indigenous Peoples
- C
Summary of Environmental and Social Aspects
- Environmental Aspects
- Involuntary Resettlement
- Indigenous Peoples
Stakeholder Communication, Participation, and Consultation
- During Project Design
- During Project Implementation
Business Opportunities
- Procurement
- Implementation Arrangements. The MOF will be the main executing agency for the project, supported by the national Task Force, chaired by the Minister of Finance. The MOH will provide technical support through the Working Group that includes the World Bank, WHO, UNICEF, and ADB. The MOH will lead the distribution and immunization of target groups with COVID-19 vaccines on the ground. The executing agency and these mechanisms will ensure coordination of the project with ADB and other development partners. The APVAX eligible vaccines will be purchased directly by the government from the vaccine manufacturer.
Contact
- Responsible ADB Officer
- Habib, Najibullah
- Responsible ADB Department
- Sectors Group
- Responsible ADB Division
- Human and Social Development Sector Office (SG-HSD)
- Executing Agencies
-
Ministry of Health (formerly Ministry of Health and Sports)
Timetable
- Concept Clearance
- -
- Fact Finding
- 02 Mar 2021 to 04 Mar 2021
- MRM
- 28 Apr 2021
- Approval
- 10 Jun 2021
- Last Review Mission
- -
- Last PDS Update
- 29 Sep 2022
Funding
Loan 4068-MON
| Approval | Signing Date | Effectivity Date | Closing | ||
|---|---|---|---|---|---|
| Original | Revised | Actual | |||
| 28 May 2021 | 28 May 2021 | 08 Jun 2021 | 31 Dec 2023 | 31 Dec 2024 | - |
| Total (Amount in US$ million) | |
|---|---|
| Project Cost | 13.32 |
| ADB | 9.50 |
| Counterpart | 3.82 |
| Cofinancing | 0.00 |
| Date | ADB | Others | Net Percentage | |
|---|---|---|---|---|
| Cumulative Contract Awards | 23 Jul 2024 | 9.13 | 0.00 | 96% |
| Cumulative Disbursements | 23 Jul 2024 | 6.55 | 0.00 | 69% |
Loan 4069-MON
| Approval | Signing Date | Effectivity Date | Closing | ||
|---|---|---|---|---|---|
| Original | Revised | Actual | |||
| 28 May 2021 | 28 May 2021 | 08 Jun 2021 | 31 Dec 2023 | 31 Dec 2024 | - |
| Total (Amount in US$ million) | |
|---|---|
| Project Cost | 9.50 |
| ADB | 9.50 |
| Counterpart | 0.00 |
| Cofinancing | 0.00 |
| Date | ADB | Others | Net Percentage | |
|---|---|---|---|---|
| Cumulative Contract Awards | 23 Jul 2024 | 9.21 | 0.00 | 97% |
| Cumulative Disbursements | 23 Jul 2024 | 6.42 | 0.00 | 68% |
Loan 8399-MON
| Approval | Signing Date | Effectivity Date | Closing | ||
|---|---|---|---|---|---|
| Original | Revised | Actual | |||
| 10 Jun 2021 | 21 Jul 2021 | 10 Nov 2021 | 31 Dec 2023 | 31 Dec 2024 | - |
| Total (Amount in US$ million) | |
|---|---|
| Project Cost | 21.00 |
| ADB | 0.00 |
| Counterpart | 0.00 |
| Cofinancing | 21.00 |
| Date | ADB | Others | Net Percentage | |
|---|---|---|---|---|
| Cumulative Contract Awards | 23 Jul 2024 | 0.00 | 20.52 | 98% |
| Cumulative Disbursements | 23 Jul 2024 | 0.00 | 10.50 | 50% |
Project Data Sheets (PDS) contain summary information on the project or program. Because the PDS is a work in progress, some information may not be included in its initial version but will be added as it becomes available. Information about proposed projects is tentative and indicative.
The Access to Information Policy (AIP) recognizes that transparency and accountability are essential to development effectiveness. It establishes the disclosure requirements for documents and information ADB produces or requires to be produced.
The Accountability Mechanism provides a forum where people adversely affected by ADB-assisted projects can voice and seek solutions to their problems and report alleged noncompliance of ADB's operational policies and procedures.
In preparing any country program or strategy, financing any project, or by making any designation of, or reference to, a particular territory or geographic area in this document, the Asian Development Bank does not intend to make any judgments as to the legal or other status of any territory or area.
Safeguard Documents See also: Safeguards
Safeguard documents provided at the time of project/facility approval may also be found in the list of linked documents provided with the Report and Recommendation of the President.
None currently available.
Evaluation Documents See also: Independent Evaluation
None currently available.
Related Publications
None currently available.
The Access to Information Policy (AIP) establishes the disclosure requirements for documents and information ADB produces or requires to be produced in its operations to facilitate stakeholder participation in ADB's decision-making. For more information, refer to the Safeguard Policy Statement, Operations Manual F1, and Operations Manual L3.
Requests for information may also be directed to the InfoUnit.
$19 Million ADB Package to Support Rollout of COVID-19 Vaccines in Mongolia
The Asian Development Bank today approved a loan package of $19 million for Mongolia to purchase safe and effective vaccines against the coronavirus disease (COVID-19).
Tenders
| Tender Title | Type | Status | Posting Date | Deadline |
|---|---|---|---|---|
| Health quality monitoring specialist | Individual - Consulting | Closed |
Contracts Awarded
Procurement Plan
| Title | Document Type | Document Date |
|---|---|---|
| Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility: Procurement Plan | Procurement Plans | Apr 2021 |